CRV431 has exerted antifibrotic activity in a number of in vitro and in vivo studies conducted by independent research laboratories
FDA Approved Opdivo demonstrated superior overall survival benefit compared to docetaxel or paclitaxel in ESCC Patients
ZEPOSIA, a treatment for multiple sclerosis is the first and only approved sphingosine-1-phosphate (S1P) receptor modulator with no genetic test…
European Commission Approves Reblozyl (luspatercept) for the Treatment of Transfusion-Dependent Anemia in Adult Patients with Myelodysplastic Syndromes or Beta Thalassemia
This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.
Read More